Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Clinics in Plastic Surgery
- Vol. 48 (4) , 651-658
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Cutaneous toxicities of RAF inhibitorsThe Lancet Oncology, 2013
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2010
- Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune ResponsesJournal of Clinical Oncology, 2006
- Phase II Multicenter Study of Neoadjuvant Biochemotherapy for Patients With Stage III Malignant MelanomaJournal of Clinical Oncology, 2006
- Distinct Sets of Genetic Alterations in MelanomaNew England Journal of Medicine, 2005
- TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITYAnnual Review of Immunology, 2005
- Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trialAnnals of Surgical Oncology, 1996